Show simple item record

dc.contributor.authorHanna, C. R.
dc.contributor.authorRobles-Zurita, J. A.
dc.contributor.authorBriggs, A.
dc.contributor.authorHarkin, A.
dc.contributor.authorKelly, C.
dc.contributor.authorMcQueen, J.
dc.contributor.authorAllan, K.
dc.contributor.authorPearson, S.
dc.contributor.authorHollander, H.
dc.contributor.authorGlimelius, B.
dc.contributor.authorSalazar, R.
dc.contributor.authorSegelov, E.
dc.contributor.authorSaunders, Mark P
dc.contributor.authorIveson, T.
dc.contributor.authorJones, R. J
dc.contributor.authorBoyd, K. A.
dc.date.accessioned2021-07-19T10:28:45Z
dc.date.available2021-07-19T10:28:45Z
dc.date.issued2021en
dc.identifier.citationHanna CR, Robles-Zurita JA, Briggs A, Harkin A, Kelly C, McQueen J, et al. Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. Clinical Colorectal Cancer. 2021 Apr;en
dc.identifier.pmid33992542en
dc.identifier.doi10.1016/j.clcc.2021.04.001en
dc.identifier.urihttp://hdl.handle.net/10541/624090
dc.description.abstractBackground: The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and methods: Individual cost-utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost-utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.clcc.2021.04.001en
dc.titleThree versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysisen
dc.typeArticleen
dc.contributor.departmentCancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotlanden
dc.identifier.journalClinical Colorectal Canceren
dc.description.noteen]
refterms.dateFOA2021-07-26T10:24:33Z


Files in this item

Thumbnail
Name:
33992542.pdf
Size:
1.467Mb
Format:
PDF
Description:
FROM CORE

This item appears in the following Collection(s)

Show simple item record